Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-424 with PEG-IFN alfa-2a and ribavirin in genotype 1 hepatitis C
NCT01753557Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Dec 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telaprevir in hepatitis C (HCV), sponsored by Mitsubishi Tanabe Pharma. Started Dec 2012; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01753557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01753557.